TCR-engineered T cell development involves modifying T cells with tumor-specific T cell receptors to recognize intracellular antigens presented by MHC molecules. This strategy enhances precision immunotherapy for solid tumors, enabling neoantigen targeting, persistence optimization, and safety profiling in preclinical and translational research.
